Venetoclax, Lenalidomide and Rituximab for Patients with Relapsed or Refractory Mantle Cell Lymphoma - Data from the Nordic Lymphoma Group NLG-MCL7 (VALERIA) Phase I Trial: Stopping Treatment in Molecular Remission Is Feasible

被引：7
|
作者：
Jerkeman, Mats
Kolstad, Arne
Niemann, Carsten Utoft
Groenbaek, Kirsten
Hutchings, Martin
Pasanen, Annika
Ekberg, Sara
Wader, Karin Fahl
Glimelius, Ingrid
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-133273
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Initial Treatment with Lenalidomide Plus Rituximab for Mantle Cell Lymphoma (MCL): 7-Year Analysis from a Multi-Center Phase II Study
    Yamshon, Samuel
    Martin, Peter
    Shah, Bijal
    Schuster, Stephen J.
    Christos, Paul J.
    Rodriguez, Amelyn
    Smith, Sonali M.
    Svoboda, Jakub
    Furman, Richard R.
    Rutherford, Sarah C.
    Allan, John N.
    Leonard, John P.
    Ruan, Jia
    BLOOD, 2020, 136
  • [42] Subcutaneous Epcoritamab Combined With Rituximab plus Lenalidomide for the Treatment of Patients with Relapsed or Refractory Follicular Lymphoma: Phase 1/2 Trial Update
    Lorenzo, Falchi
    Sirpa, Leppa
    Wahlin, Bjorn E.
    Marcel, Nijland
    Christensen, Jacob H.
    De, Vos Sven
    Harald, Holte
    Linton, Kim M.
    Aqeel, Abbas
    Wang Liwei
    Minh, Dinh
    Brian, Elliott
    David, Belada
    AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 : S31 - S31
  • [43] Phase 1b dose-finding study of rituximab, lenalidomide, and ibrutinib (R2I) in patients with relapsed/refractory mantle cell lymphoma
    Ip, Andrew
    Petrillo, Alessandra
    Della Pia, Alexandra
    Lee, Geeny G.
    Gill, Sarvarinder
    Varughese, Tony
    Zenreich, Joshua
    Gutierrez, Martin
    Zhang, Jiayu
    Ahn, Jaeil
    Bharani, Vishnu
    Nejad, Ava S.
    Pascual, Lauren
    Feldman, Tatyana A.
    Leslie, Lori A.
    Goy, Andre H.
    LEUKEMIA & LYMPHOMA, 2023, 64 (14) : 2225 - 2235
  • [44] Temsirolimus in Combination with Bendamustine and Rituximab for the Treatment of Relapsed Mantle Cell and Follicular Lymphoma: Report on An Ongoing Phase I/II Trial
    Hess, Georg
    Keller, Ulrich
    Atta, Johannes
    Buske, Christian
    Borchmann, Peter
    Medler, Christoph
    Witzens-Harig, Mathias
    Dreyling, Martin H.
    BLOOD, 2011, 118 (21) : 1159 - 1159
  • [45] Temsirolimus in Combination with Bendamustine and Rituximab for the Treatment of Relapsed Mantle Cell and Follicular Lymphoma: Report on an Ongoing Phase I/II Trial
    Hess, Georg
    Keller, Ulrich
    Atta, Johannes
    Bitz, Ulrich
    Lerchenmueller, Christian
    Karola, Wagner
    Medler, Christoph
    Ruckes, Christian
    Witzens-Harig, Mathias
    Huebel, Kai
    LaRosee, Paul
    Dreyling, Martin H.
    BLOOD, 2015, 126 (23)
  • [46] Safety and efficacy of acalabrutinib plus bendamustine and rituximab in patients with treatment-naïve or relapsed/refractory mantle cell lymphoma: phase Ib trial
    Phillips, Tycel
    Wang, Michael
    Robak, Tadeusz
    Gallinson, David
    Stevens, Don
    Patel, Krish
    Ramadan, Safaa
    Wun, Chuan-Chuan
    Jurczak, Wojciech
    Smith, Stephen D.
    HAEMATOLOGICA, 2025, 110 (03) : 715 - 724
  • [47] SINGLE-AGENT LENALIDOMIDE IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA FOLLOWING BORTEZOMIB: EFFICACY, SAFETY AND PHARMACOKINETICS FROM THE MULTICENTER PHASE II MCL-001 "EMERGE" TRIAL
    Goy, A.
    Sinha, R.
    Vose, J.
    Adler, H.
    Bernstein, S.
    Robertson, M.
    Chen, N.
    Zhang, L.
    Cicero, S.
    Fu, T.
    Witzig, T.
    HAEMATOLOGICA, 2013, 98 : 478 - 478
  • [48] Bortezomib, rituximab, and dexamethason (BORID) as salvage treatment in relapsed/refractory mantle cell lymphoma: Sustained disease control in patients achieving a complete remission
    Drach, Johannes
    Kaufmann, Hannes
    Pichelmayer, Oskar
    Sagaster, Verena
    Holzer, Sonja
    Odelga, Viktoria
    Zielinski, Christoph
    Raderer, Markus
    BLOOD, 2007, 110 (11) : 760A - 760A
  • [49] Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL)
    Jain, Preetesh
    Romaguera, Jorge
    Srour, Samer A.
    Lee, Hun J.
    Hagemeister, Frederick
    Westin, Jason
    Fayad, Luis
    Samaniego, Felipe
    Badillo, Maria
    Zhang, Liang
    Nastoupil, Lorreta
    Kanagal-Shamanna, Rashmi
    Fowler, Nathan
    Wang, Michael L.
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 182 (03) : 404 - 411
  • [50] Excessive neurotoxicity in a phase II trial of combined bortezomib and rituximab in patients with relapsed/refractory mantle cell (MCL) and follicular (FL) non-Hodgkin's lymphoma.
    Blum, Kristie A.
    Lucas, Margaret S.
    Johnston, Jeffrey S.
    Dalton, James
    Young, Donn
    Baiocchi, Robert A.
    Lin, Thomas S.
    Porcu, Pierluigi
    Byrd, John C.
    BLOOD, 2006, 108 (11) : 784A - 784A
12345